| Overview |
| bsm-63027r-pe-cy55-100ul |
| MEK5 Recombinant Monoclonal Antibody, PE-Cy5.5 Conjugated |
| WB |
| Human |
| Specifications |
| PE-Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from human MEK5 |
| Monoclonal |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 5607 |
| Q13163 |
| MAP2K5; HsT17454; MAPKK 5; MEK 5; MAPKK5; MEK5; MKK5; MAP kinase kinase 5; PRKMK5; MAP kinase kinase MEK5b; MAPK/ERK kinase 5. |
| Acts as a scaffold for the formation of a ternary MAP3K2/MAP3K3-MAP3K5-MAPK7 signaling complex. Activation of this pathway appears to play a critical role in protecting cells from stress-induced apoptosis, neuronal survival and cardiac development and angiogenesis. As part of the MAPK/ERK signaling pathway, acts as a negative regulator of apoptosis in cardiomyocytes via promotion of STUB1/CHIP-mediated ubiquitination and degradation of ICER-type isoforms of CREM. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz